EGFR is a tumor-associated antigen that is also expressed in normal tissue, although at a substantially lower level; therefore, evaluating the on-target, off-tumor (OTOT) toxicity associated with 7D12-T cell therapy is imperative, especially for hIL21-armed 7D12-T cells [31]. The gene discussed is EGFR; the disease is neoplasm.